From a gene transcript expression analysis of eight primary multiple myeloma patient samples that relapsed after chemotherapy, BCL2A1 was identified as the most frequently increased factor, suggesting its therapy resistant role in multiple myeloma [60]. This evidence concerns the gene BCL2A1 and plasma cell myeloma.